Misplaced Pages

Kasugamycin: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editContent deleted Content addedVisualWikitext
Revision as of 08:27, 26 May 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{chembox}} (changes to verified fields - updated 'UNII_Ref', 'ChEMBL_Ref', 'KEGG_Ref') per Chem/Drugbox validation (report errors or [[user talk← Previous edit Latest revision as of 03:17, 21 December 2024 edit undoMr.choppers (talk | contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers69,351 edits Undid revision 1263815862 by PragyaanRover (talk) WP:OVERLINKTag: Undo 
(30 intermediate revisions by 19 users not shown)
Line 1: Line 1:
{{Chembox {{Chembox
| Verifiedfields = changed | Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 400126667 | verifiedrevid = 442175301
| ImageFile = Kasugamycin.png | ImageFile = Kasugamycin structure.svg
| ImageSize = 200px | ImageSize = 200px
| IUPACName = 2-amino-2-oxyoxan-3-yl]iminoacetic acid | IUPACName = 2-amino-2-oxyoxan-3-yl]iminoacetic acid
Line 15: Line 16:
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = PVTHJAPFENJVNC-MHRBZPPQSA-N | StdInChIKey = PVTHJAPFENJVNC-MHRBZPPQSA-N
| CASNo_Ref = {{cascite|correct|??}}
| CASNo = 6980-18-3 | CASNo = 6980-18-3
| CASNo2_Ref = {{cascite|correct|CAS}}
⚫ | CASOther = <br>19408-46-9 (])
| CASNo2 = 19408-46-9
| CASNo2_Comment = (])
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = O957UYB9DY
| UNII2 = SXA18D440T
| UNII2_Ref = {{fdacite|correct|FDA}}
⚫ | UNII2_Comment = (])
| PubChem = 65174 | PubChem = 65174
| KEGG_Ref = {{keggcite|changed|kegg}} | KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = C17968 | KEGG = C17968
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 81419
| SMILES = OC(=O)C(=N)N2C(N)(O1(O)(O)(O)(O)1O)O2C | SMILES = OC(=O)C(=N)N2C(N)(O1(O)(O)(O)(O)1O)O2C
}} }}
| Section2 = {{Chembox Properties | Section2 = {{Chembox Properties
| C=14|H=27|N=3|O=10 | C=14|H=25|N=3|O=9
| Appearance = | Appearance =
| Density = | Density =
| MeltingPt = | MeltingPt =
| BoilingPt = | BoilingPt =
| Solubility = }} | Solubility = }}
| Section3 = {{Chembox Hazards | Section3 = {{Chembox Hazards
| MainHazards = | MainHazards =
| FlashPt = | FlashPt =
| Autoignition = }} | AutoignitionPt = }}
}} }}


'''Kasugamycin''' (Ksg) is an ] ] that was originally isolated in 1965, from ''Streptomyces kasugaensis'', a '']'' strain found near the Kasuga shrine in Nara, ]. Kasugamycin was discovered by ], who also discovered ] and ], as a drug which could prevent growth of a fungus causing rice blast disease. It was later found to inhibit bacterial growth also. It exists as a white, crystalline substance with the chemical formula C<sub>14</sub>H<sub>28</sub>ClN<sub>3</sub>O<sub>10</sub> (kasugamycin hydrochloride). It is also known as kasumin. '''Kasugamycin''' (Ksg) is an ] ] that was originally isolated in 1965, from '']'', a '']'' strain found near the ] in ], ]. Kasugamycin was discovered by ], who also discovered ] and ], as a drug that prevent growth of a fungus causing ]. It was later found to inhibit bacterial growth also. It exists as a white, crystalline substance with the chemical formula C<sub>14</sub>H<sub>28</sub>ClN<sub>3</sub>O<sub>10</sub> (kasugamycin hydrochloride). It is also known as kasumin.<ref>{{cite encyclopedia |author=Franz Müller |author2=Peter Ackermann |author3=Paul Margot |title=Fungicides, Agricultural, 2. Individual Fungicides|encyclopedia=Ullmann's Encyclopedia of Industrial Chemistry|publisher=Wiley-VCH|place=Weinheim|year=2012|doi=10.1002/14356007.o12_o06|isbn=978-3-527-30673-2 }}</ref>


==Mechanism of action== ==Mechanism of action==
Like many of the known natural ], kasugamycin inhibits proliferation of bacteria by tampering with their ability to make new ], the ] being the major target. Kasugamycin inhibits protein synthesis at the step of ] initiation. Kasugamycin inhibition is thought to occur by direct competition with initiator ]. Recent experiments suggest that kasugamycin indirectly induces dissociation of P-site-bound fMet-tRNA<sup>fMet</sup> from 30S subunits through perturbation of the ], thereby interfering with translation initiation. Like many of the known natural ]s, kasugamycin inhibits proliferation of bacteria by tampering with their ability to make new ]s, the ] being the major target. Kasugamycin inhibits protein synthesis at the step of ] initiation. Kasugamycin inhibition is thought to occur by direct competition with initiator ]. Recent experiments suggest that kasugamycin indirectly induces dissociation of P-site-bound fMet-tRNA<sup>fMet</sup> from 30S subunits through perturbation of the ], thereby interfering with translation initiation.{{cn|date=March 2023}}


Kasugamycin specifically inhibits translation initiation of canonical but not of leaderless mRNA. For initiation on leaderless mRNA, the overlap between mRNA and kasugamycin is reduced and the binding of tRNA is further stabilized by the presence of the 50S subunit, minimizing Ksg efficacy. Kasugamycin specifically inhibits translation initiation of canonical but not of leaderless mRNA. For initiation on leaderless mRNA, the overlap between mRNA and kasugamycin is reduced and the binding of tRNA is further stabilized by the presence of the 50S subunit, minimizing Ksg efficacy.
Kasugamycin also induces the formation of unusual 61S ribosomes in vivo, which are proficient in selectively translating leaderless mRNA. 61S particles are stable and are devoid of more than six proteins of the small subunit, including the functionally important proteins S1 and S12. Kasugamycin also induces the formation of unusual 61S ribosomes in vivo, which are proficient in selectively translating leaderless mRNA. 61S particles are stable and are devoid of more than six proteins of the small subunit, including the functionally important proteins S1 and S12.{{cn|date=March 2023}}


==Structural basis for kasugamycin action== ==Structural basis for kasugamycin action==
The ] of kasugamycin in complex with the ''Escherichia coli'' 70S ribosome has been determined at 3.5-A resolution. The structure reveals that the drug binds within the messenger RNA channel of the 30S subunit between the universally conserved G926 and A794 nucleotides in 16S ], which are sites of kasugamycin resistance. The kasugamycin binding sites are present on top of helix 44 (h44), spanning the region between h24 and h28, which contacts the conserved nucleotides A794 and G926. Neither binding position overlaps with P-site tRNA. Instead, kasugamycin mimics the codon nucleotides at the P and E sites by binding within the path of the mRNA, thus perturbing the mRNA-tRNA codon-anticodon interaction. The structure of the kasugamycin-70S ribosome complex from ''Escherichia coli'' has been determined by ] at 3.5-A resolution. The drug binds within the messenger RNA channel of the 30S subunit between the universally conserved G926 and A794 nucleotides in 16S ], which are sites of kasugamycin resistance. The kasugamycin binding sites are present on top of helix 44 (h44), spanning the region between h24 and h28, which contacts the conserved nucleotides A794 and G926. Neither binding position overlaps with P-site tRNA. Instead, kasugamycin mimics the codon nucleotides at the P and E sites by binding within the path of the mRNA, thus perturbing the mRNA-tRNA codon-anticodon interaction.{{cn|date=March 2023}}


==Resistance== ==Resistance==
Low level resistance to kasugamycin is acquired by ] in the 16S rRNA ] KsgA which ] the nucleotides A1518 and A1519 in 16S rRNA. Spontaneous ksgA mutations conferring a modest level of resistance to kasugamycin occur at a high frequency of 10<sup>–6</sup>. Once cells acquire the ksgA mutations, they produce high-level kasugamycin resistance at an extraordinarily high frequency (100-fold greater frequency than that observed in the ksgA+ strain). Low level resistance to kasugamycin is acquired by ]s in the 16S rRNA ] KsgA which ] the nucleotides A1518 and A1519 in 16S rRNA. Spontaneous ksgA mutations conferring a modest level of resistance to kasugamycin occur at a high frequency of 10<sup>−6</sup>. Once cells acquire the ksgA mutations, they produce high-level kasugamycin resistance at an extraordinarily high frequency (100-fold greater frequency than that observed in the ksgA+ strain).{{cn|date=March 2023}}


Surprisingly, kasugamycin resistance mutations do not inhibit binding of the drug to the ribosome. Present structural and biochemical results indicate that inhibition by kasugamycin and kasugamycin resistance are closely linked to the structure of the mRNA at the junction of the peptidyl-tRNA and exit-tRNA sites (P and E sites). Surprisingly, kasugamycin resistance mutations do not inhibit binding of the drug to the ribosome. Present structural and biochemical results indicate that inhibition by kasugamycin and kasugamycin resistance are closely linked to the structure of the mRNA at the junction of the peptidyl-tRNA and exit-tRNA sites (P and E sites){{cn|date=March 2023}}


==References== ==References==
<references />
⚫ 1. Okuyama, A., Machiyama, N., Kinoshita, T., and Tanaka, N. (1971). Inhibition by kasugamycin of initiation complex formation on 30S ribosomes. Biochem. Biophys. Res. Commun. 43, 196–199.


==Further reading==
2. Schluenzen, F., Takemoto, C., Wilson, D.N., Kaminishi, T., Harms, J.M., Hanawa-Suetsugu, K., Szaflarski, W., Kawazoe, M., Shirouzu, M., Nierhaus, K.H., et al. (2006). The antibiotic kasugamycin mimics mRNA nucleotides to destabilize tRNA binding and inhibit canonical translation initiation. Nat. Struct. Mol. Biol. 13, 871–878.
⚫ 1. Okuyama, A., Machiyama, N., Kinoshita, T., and Tanaka, N. (1971). Inhibition by kasugamycin of initiation complex formation on 30S ribosomes. Biochem. Biophys. Res. Commun. 43, 196–199.


3. Schuwirth, B.S., Day, J.M., Hau, C.W., Janssen, G.R., Dahlberg, A.E., Cate, J.H., and Vila-Sanjurjo, A. (2006). Structural analysis of kasugamycin inhibition of translation. Nat. Struct. Mol. Biol. 13, 879–886. 2. Schluenzen, F., Takemoto, C., Wilson, D.N., Kaminishi, T., Harms, J.M., Hanawa-Suetsugu, K., Szaflarski, W., Kawazoe, M., Shirouzu, M., Nierhaus, K.H., et al. (2006). The antibiotic kasugamycin mimics mRNA nucleotides to destabilize tRNA binding and inhibit canonical translation initiation. Nat. Struct. Mol. Biol. 13, 871–878.


3. Schuwirth, B.S., Day, J.M., Hau, C.W., Janssen, G.R., Dahlberg, A.E., Cate, J.H., and Vila-Sanjurjo, A. (2006). Structural analysis of kasugamycin inhibition of translation. Nat. Struct. Mol. Biol. 13, 879–886.
⚫ 4. Kaberdina A.C., Szaflarski W., Nierhaus K.H., and Moll I. (2009). An Unexpected Type of Ribosomes Induced by Kasugamycin: A Look into Ancestral Times of Protein Synthesis?. Mol. Cell. 33(2):141-2.


⚫ 4. Kaberdina A.C., Szaflarski W., Nierhaus K.H., and Moll I. (2009). An Unexpected Type of Ribosomes Induced by Kasugamycin: A Look into Ancestral Times of Protein Synthesis?. Mol. Cell. 33(2):141-2.
⚫ 5. Ochi K., Kim J., Tanaka Y., Wang G., Masuda K., Nanamiya H., Okamoto S., Tokuyama S., Adachi Y. and Kawamura F. (2009). Inactivation of KsgA, a 16S rRNA Methyltransferase, Causes Vigorous Emergence of Mutants with High-Level Kasugamycin Resistance. Antimicrobial Agents and Chemotherapy, 53,1 (193-201).

⚫ 6. Mankin A. (2006). Antibiotic blocks mRNA path on the ribosome. Nature Structural & Molecular Biology - 13, 858 – 860.


⚫ 5. Ochi K., Kim J., Tanaka Y., Wang G., Masuda K., Nanamiya H., Okamoto S., Tokuyama S., Adachi Y. and Kawamura F. (2009). Inactivation of KsgA, a 16S rRNA Methyltransferase, Causes Vigorous Emergence of Mutants with High-Level Kasugamycin Resistance. Antimicrobial Agents and Chemotherapy, 53,1 (193-201).


⚫ 6. Mankin A. (2006). Antibiotic blocks mRNA path on the ribosome. Nature Structural & Molecular Biology - 13, 858 – 860.


] ]

]

Latest revision as of 03:17, 21 December 2024

Kasugamycin
Names
IUPAC name 2-amino-2-oxyoxan-3-yl]iminoacetic acid
Other names Kasumin; 3-O--2,3,4,6-tetradeoxy-D-arabino-hexopyranosyl]-D-chiro-inositol
Identifiers
CAS Number
3D model (JSmol)
ChEBI
ChemSpider
ECHA InfoCard 100.116.563 Edit this at Wikidata
KEGG
PubChem CID
UNII
CompTox Dashboard (EPA)
InChI
  • InChI=1S/C14H25N3O9/c1-3-5(17-12(16)13(23)24)2-4(15)14(25-3)26-11-9(21)7(19)6(18)8(20)10(11)22/h3-11,14,18-22H,2,15H2,1H3,(H2,16,17)(H,23,24)/t3-,4+,5+,6-,7+,8+,9-,10+,11+,14-/m1/s1Key: PVTHJAPFENJVNC-MHRBZPPQSA-N
  • InChI=1/C14H25N3O9/c1-3-5(17-12(16)13(23)24)2-4(15)14(25-3)26-11-9(21)7(19)6(18)8(20)10(11)22/h3-11,14,18-22H,2,15H2,1H3,(H2,16,17)(H,23,24)/t3-,4+,5+,6-,7+,8+,9-,10+,11+,14-/m1/s1Key: PVTHJAPFENJVNC-MHRBZPPQBX
SMILES
  • OC(=O)C(=N)N2C(N)(O1(O)(O)(O)(O)1O)O2C
Properties
Chemical formula C14H25N3O9
Molar mass 379.366 g·mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). ☒N verify (what is  ?) Infobox references
Chemical compound

Kasugamycin (Ksg) is an aminoglycoside antibiotic that was originally isolated in 1965, from Streptomyces kasugaensis, a Streptomyces strain found near the Kasuga shrine in Nara, Japan. Kasugamycin was discovered by Hamao Umezawa, who also discovered kanamycin and bleomycin, as a drug that prevent growth of a fungus causing rice blast disease. It was later found to inhibit bacterial growth also. It exists as a white, crystalline substance with the chemical formula C14H28ClN3O10 (kasugamycin hydrochloride). It is also known as kasumin.

Mechanism of action

Like many of the known natural antibiotics, kasugamycin inhibits proliferation of bacteria by tampering with their ability to make new proteins, the ribosome being the major target. Kasugamycin inhibits protein synthesis at the step of translation initiation. Kasugamycin inhibition is thought to occur by direct competition with initiator transfer RNA. Recent experiments suggest that kasugamycin indirectly induces dissociation of P-site-bound fMet-tRNA from 30S subunits through perturbation of the mRNA, thereby interfering with translation initiation.

Kasugamycin specifically inhibits translation initiation of canonical but not of leaderless mRNA. For initiation on leaderless mRNA, the overlap between mRNA and kasugamycin is reduced and the binding of tRNA is further stabilized by the presence of the 50S subunit, minimizing Ksg efficacy. Kasugamycin also induces the formation of unusual 61S ribosomes in vivo, which are proficient in selectively translating leaderless mRNA. 61S particles are stable and are devoid of more than six proteins of the small subunit, including the functionally important proteins S1 and S12.

Structural basis for kasugamycin action

The structure of the kasugamycin-70S ribosome complex from Escherichia coli has been determined by X-ray crystallography at 3.5-A resolution. The drug binds within the messenger RNA channel of the 30S subunit between the universally conserved G926 and A794 nucleotides in 16S ribosomal RNA, which are sites of kasugamycin resistance. The kasugamycin binding sites are present on top of helix 44 (h44), spanning the region between h24 and h28, which contacts the conserved nucleotides A794 and G926. Neither binding position overlaps with P-site tRNA. Instead, kasugamycin mimics the codon nucleotides at the P and E sites by binding within the path of the mRNA, thus perturbing the mRNA-tRNA codon-anticodon interaction.

Resistance

Low level resistance to kasugamycin is acquired by mutations in the 16S rRNA methyltransferase KsgA which methylates the nucleotides A1518 and A1519 in 16S rRNA. Spontaneous ksgA mutations conferring a modest level of resistance to kasugamycin occur at a high frequency of 10. Once cells acquire the ksgA mutations, they produce high-level kasugamycin resistance at an extraordinarily high frequency (100-fold greater frequency than that observed in the ksgA+ strain).

Surprisingly, kasugamycin resistance mutations do not inhibit binding of the drug to the ribosome. Present structural and biochemical results indicate that inhibition by kasugamycin and kasugamycin resistance are closely linked to the structure of the mRNA at the junction of the peptidyl-tRNA and exit-tRNA sites (P and E sites)

References

  1. Franz Müller; Peter Ackermann; Paul Margot (2012). "Fungicides, Agricultural, 2. Individual Fungicides". Ullmann's Encyclopedia of Industrial Chemistry. Weinheim: Wiley-VCH. doi:10.1002/14356007.o12_o06. ISBN 978-3-527-30673-2.

Further reading

1. Okuyama, A., Machiyama, N., Kinoshita, T., and Tanaka, N. (1971). Inhibition by kasugamycin of initiation complex formation on 30S ribosomes. Biochem. Biophys. Res. Commun. 43, 196–199.

2. Schluenzen, F., Takemoto, C., Wilson, D.N., Kaminishi, T., Harms, J.M., Hanawa-Suetsugu, K., Szaflarski, W., Kawazoe, M., Shirouzu, M., Nierhaus, K.H., et al. (2006). The antibiotic kasugamycin mimics mRNA nucleotides to destabilize tRNA binding and inhibit canonical translation initiation. Nat. Struct. Mol. Biol. 13, 871–878.

3. Schuwirth, B.S., Day, J.M., Hau, C.W., Janssen, G.R., Dahlberg, A.E., Cate, J.H., and Vila-Sanjurjo, A. (2006). Structural analysis of kasugamycin inhibition of translation. Nat. Struct. Mol. Biol. 13, 879–886.

4. Kaberdina A.C., Szaflarski W., Nierhaus K.H., and Moll I. (2009). An Unexpected Type of Ribosomes Induced by Kasugamycin: A Look into Ancestral Times of Protein Synthesis?. Mol. Cell. 33(2):141-2.

5. Ochi K., Kim J., Tanaka Y., Wang G., Masuda K., Nanamiya H., Okamoto S., Tokuyama S., Adachi Y. and Kawamura F. (2009). Inactivation of KsgA, a 16S rRNA Methyltransferase, Causes Vigorous Emergence of Mutants with High-Level Kasugamycin Resistance. Antimicrobial Agents and Chemotherapy, 53,1 (193-201).

6. Mankin A. (2006). Antibiotic blocks mRNA path on the ribosome. Nature Structural & Molecular Biology - 13, 858 – 860.

Category: